- Pelthos Therapeutics Inc. **commercially launched ZELSUVMI™** (berdazimer) topical gel, 10.3%, in **July 2025**.  **[1919246_0001753926-25-001425_g084940_ex99-1.htm:2]** **[1919246_0001753926-25-001425_g084940_ex99-1.htm:6]**  ZELSUVMI™ is the **first and only FDA-approved at-home treatment** for _molluscum contagiosum_, having received FDA approval in **January 2024**.  **[1919246_0001753926-25-001425_g084940_ex99-2.htm:0]** **[1919246_0001753926-25-001425_g084940_ex99-1.htm:6]** 
- The company forecasts **peak net revenue of $175 million per annum by 2028** for ZELSUVMI™, targeting a total addressable market for _molluscum contagiosum_ in excess of **$20 billion** with up to **6 million annual cases** in the U.S..  **[1919246_0001753926-25-001425_g084940_ex99-1.htm:2]** **[1919246_0001753926-25-001425_g084940_ex99-1.htm:6]**  
- In its early launch phase, ZELSUVMI™ recorded **892 TRx Units** and **501 unique prescribers** by **August 22, 2025**.   
- CEO Scott Plesha and CFO Frank Knuettel are scheduled to present at the **2025 Wells Fargo Healthcare Conference** on **September 3, 2025**, to provide updates on the product pipeline and the commercial launch of ZELSUVMI™.  **[1919246_0001753926-25-001425_g084940_ex99-2.htm:0]** **[1919246_0001753926-25-001425_g084940_8-k.htm:1]**

Pelthos Therapeutics (PTHS)